|
Press Releases |
|
|
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物、海外製品名:「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
Thursday, March 21, 2024 |
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
Wednesday, July 31, 2019 |
|
エーザイ、E2082の臨床第I相試験(治験)における死亡例の発生について |
当社が日本国内で実施していた健康成人を対象とした臨床第I相試験(治験)において、2019 年6 月に、1 名の被験者様が治験薬の投与を完了後にお亡くなりになりました。被験者様のご冥福をお祈り申し上げると共に、ご遺族様には謹んでお悔やみ申し上げます。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Kontent.ai Introduces Mission Control and New Brand Identity, Leading a New Era of Content Management
Apr 24, 2024 20:51 HKT/SGT
|
|
|
业聚医疗合资企业在中国内地启动TricValve临床试验
Apr 24, 2024 19:07 HKT/SGT
|
|
|
業聚醫療合資企業在中國內地啟動TricValve臨床試驗
Apr 24, 2024 19:04 HKT/SGT
|
|
|
OrbusNeich's Joint Venture Kicks Off TricValve Clinical Trial in Mainland China
Apr 24, 2024 18:59 HKT/SGT
|
|
|
Legacy Credit Emerges as a Substantial Shareholder in VCI Global
Apr 24, 2024 18:00 HKT/SGT
|
|
|
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
|
|
|
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
|
|
|
三菱重工、タイの超大型複合火力発電所プロジェクトでM701JAC形GTCCの7系列目が運転開始
Apr 24, 2024 14:30: JST
|
|
|
トヨタ・モビリティ基金、「自転車事故削減に向けた新たな官民連携のあり方」に関するシンポジウムを開催
Apr 24, 2024 14:00: JST
|
|
|
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
|
|
|
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
|
|
|
一站式金融媒体发布平台「全球速发布」重磅推出!
Apr 24, 2024 10:52 HKT/SGT
|
|
|
一站式金融媒體發佈平台「全球速發佈」重磅推出!
Apr 24, 2024 10:35 HKT/SGT
|
|
|
Honda、新型SUV「WR-V」受注状況について
Apr 24, 2024 10:00: JST
|
|
|
三菱みなとみらい技術館に「空・宇宙ゾーン」を新設、リニューアルオープン
Apr 24, 2024 10:00: JST
|
|
|
|
More News >> |
|
|
|
|
|